For prognostication, pre- and posttherapeutic analyses alike of KRAS and APC mutations provided information on tumor load (quantitative analysis) and allowed molecular profiling (qualitative analysis) to guide treatment decisions by determining the indication for (neo-)adjuvant therapies (19,20,124). Here, APC is linked to neoplasm.